- Home
- SCM vs ENGN Comparison
SCM vs ENGN Comparison
Compare SCM & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCM
- ENGN
- Stock Information
- Founded
- SCM 2012
- ENGN 1999
- Country
- SCM United States
- ENGN Canada
- Employees
- SCM N/A
- ENGN N/A
- Industry
- SCM Finance/Investors Services
- ENGN
- Sector
- SCM Finance
- ENGN
- Exchange
- SCM Nasdaq
- ENGN Nasdaq
- Market Cap
- SCM 361.0M
- ENGN 317.6M
- IPO Year
- SCM 2012
- ENGN N/A
- Fundamental
- Price
- SCM $14.30
- ENGN $7.33
- Analyst Decision
- SCM Hold
- ENGN Strong Buy
- Analyst Count
- SCM 2
- ENGN 9
- Target Price
- SCM $13.63
- ENGN $29.78
- AVG Volume (30 Days)
- SCM 124.9K
- ENGN 112.9K
- Earning Date
- SCM 03-03-2025
- ENGN 03-10-2025
- Dividend Yield
- SCM 11.16%
- ENGN N/A
- EPS Growth
- SCM 307.51
- ENGN N/A
- EPS
- SCM 1.96
- ENGN N/A
- Revenue
- SCM $107,143,385.00
- ENGN N/A
- Revenue This Year
- SCM $0.34
- ENGN N/A
- Revenue Next Year
- SCM N/A
- ENGN N/A
- P/E Ratio
- SCM $7.30
- ENGN N/A
- Revenue Growth
- SCM 5.88
- ENGN N/A
- 52 Week Low
- SCM $12.48
- ENGN $4.42
- 52 Week High
- SCM $14.68
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- SCM 69.76
- ENGN 43.95
- Support Level
- SCM $13.50
- ENGN $7.00
- Resistance Level
- SCM $13.80
- ENGN $8.40
- Average True Range (ATR)
- SCM 0.16
- ENGN 1.00
- MACD
- SCM 0.07
- ENGN 0.02
- Stochastic Oscillator
- SCM 97.32
- ENGN 32.13
About SCM Stellus Capital Investment Corporation
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. Business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.